viking therapeutics inc. - VKTX
VKTX
Close Chg Chg %
51.53 0.10 0.19%
Closed Market
51.63
+0.10 (0.19%)
Volume: 3.29M
Last Updated:
Nov 21, 2024, 4:00 PM EDT
Company Overview: viking therapeutics inc. - VKTX
VKTX Key Data
| Open $51.30 | Day Range 50.56 - 54.28 |
| 52 Week Range 11.21 - 99.41 | Market Cap $5.74B |
| Shares Outstanding 111.44M | Public Float 108.05M |
| Beta 0.99 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.94 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 6.64M |
VKTX Performance
| 1 Week | 3.93% | ||
| 1 Month | -33.96% | ||
| 3 Months | -20.27% | ||
| 1 Year | 319.63% | ||
| 5 Years | 617.69% |
VKTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About viking therapeutics inc. - VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
VKTX At a Glance
Viking Therapeutics, Inc.
9920 Pacific Heights Boulevard
San Diego, California 92121
| Phone | 1-858-704-4660 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -85,895,000.00 | |
| Sector | Health Technology | Employees | 27 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
VKTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.347 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.876 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
VKTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,181,296.296 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VKTX Liquidity
| Current Ratio | 19.191 |
| Quick Ratio | 19.191 |
| Cash Ratio | 18.922 |
VKTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.99 |
| Return on Equity | -34.794 |
| Return on Total Capital | -24.564 |
| Return on Invested Capital | -34.639 |
VKTX Capital Structure
| Total Debt to Total Equity | 0.362 |
| Total Debt to Total Capital | 0.36 |
| Total Debt to Total Assets | 0.342 |
| Long-Term Debt to Equity | 0.269 |
| Long-Term Debt to Total Capital | 0.268 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Viking Therapeutics Inc. - VKTX
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 277.00K | 296.00K | 291.00K | 292.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 277.00K | 296.00K | 291.00K | 292.00K | |
Depreciation
| 277.00K | 296.00K | 291.00K | 292.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +6.54% | +6.86% | -1.69% | +0.34% | |
Gross Income
| (277.00K) | (296.00K) | (291.00K) | (292.00K) | |
Gross Income Growth
| -6.54% | -6.86% | +1.69% | -0.34% | |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 42.38M | 55.39M | 70.06M | 100.53M | |
Research & Development
| 31.93M | 44.98M | 54.23M | 63.81M | |
Other SG&A
| 10.45M | 10.40M | 15.83M | 36.73M | |
SGA Growth
| +30.71% | +30.67% | +26.50% | +43.49% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (42.66M) | (55.68M) | (70.36M) | (100.83M) | |
Non Operating Income/Expense
| 3.27M | 710.00K | 1.55M | 15.02M | |
Non-Operating Interest Income
| 3.23M | 703.00K | 1.59M | 15.02M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 106.00K | 18.00K | 59.00K | 88.00K | |
Interest Expense Growth
| -27.40% | -83.02% | +227.78% | +49.15% | |
Gross Interest Expense
| 106.00K | 18.00K | 59.00K | 88.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (39.49M) | (54.99M) | (68.87M) | (85.89M) | |
Pretax Income Growth
| -53.21% | -39.23% | -25.24% | -24.73% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | 12.72M | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | (12.72M) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (39.49M) | (54.99M) | (68.87M) | (85.89M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (39.49M) | (54.99M) | (68.87M) | (85.89M) | |
Net Income Growth
| -53.21% | -39.23% | -25.24% | -24.73% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (39.49M) | (54.99M) | (68.87M) | (85.89M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (39.49M) | (54.99M) | (68.87M) | (85.89M) | |
EPS (Basic)
| -0.544 | -0.7123 | -0.8963 | -0.9104 | |
EPS (Basic) Growth
| -51.87% | -30.94% | -25.83% | -1.57% | |
Basic Shares Outstanding
| 72.60M | 77.20M | 76.83M | 94.35M | |
EPS (Diluted)
| -0.544 | -0.7123 | -0.8963 | -0.9104 | |
EPS (Diluted) Growth
| -51.87% | -30.94% | -25.83% | -1.57% | |
Diluted Shares Outstanding
| 72.60M | 77.20M | 76.83M | 94.35M | |
EBITDA
| (42.38M) | (55.39M) | (70.06M) | (100.53M) | |
EBITDA Growth
| -30.71% | -30.67% | -26.50% | -43.49% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 109.923 | |
| Number of Ratings | 13 | Current Quarters Estimate | -0.283 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.97 | |
| Last Quarter’s Earnings | -0.22 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.91 | Next Fiscal Year Estimate | -1.512 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 3 | 11 | 12 |
| Mean Estimate | -0.28 | -0.31 | -0.97 | -1.51 |
| High Estimates | -0.24 | -0.28 | -0.92 | -1.15 |
| Low Estimate | -0.34 | -0.37 | -1.09 | -2.07 |
| Coefficient of Variance | -13.27 | -15.74 | -5.23 | -20.21 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 13 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Viking Therapeutics Inc. - VKTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Viking Therapeutics Inc. - VKTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 23, 2024 | J. Matthew Singleton Director | 10,300 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 23, 2024 | Brian Lian President & CEO; Director | 2,355,927 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.77 per share | 18,305,552.79 |
| Aug 23, 2024 | J. Matthew Singleton Director | 9,500 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.72 per share | 662,340.00 |
| Aug 23, 2024 | J. Matthew Singleton Director | 15,200 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.19 per share | 18,088.00 |
| Aug 23, 2024 | Brian Lian President & CEO; Director | 2,354,927 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.9 per share | 164,609,397.30 |
| Aug 23, 2024 | Brian Lian President & CEO; Director | 231,130 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Brian Lian President & CEO; Director | 2,354,927 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.12 per share | 158,062,700.24 |
| Aug 20, 2024 | J. Matthew Singleton Director | 15,444 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $61.86 per share | 955,365.84 |
| Aug 20, 2024 | J. Matthew Singleton Director | 13,389 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $63.15 per share | 845,515.35 |
| Aug 20, 2024 | J. Matthew Singleton Director | 11,001 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.1 per share | 705,164.10 |
| Aug 20, 2024 | J. Matthew Singleton Director | 9,500 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.88 per share | 616,360.00 |
| Aug 20, 2024 | J. Matthew Singleton Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Brian Lian President & CEO; Director | 232,130 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 1, 2024 | Gregory S. Zante Chief Financial Officer | 187,052 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.71 per share | 10,981,822.92 |
| Aug 1, 2024 | Gregory S. Zante Chief Financial Officer | 190,526 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $56.96 per share | 10,852,360.96 |
| Aug 1, 2024 | Gregory S. Zante Chief Financial Officer | 181,521 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 1, 2024 | Marianne Mancini Chief Operating Officer | 358,508 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 1, 2024 | Marianne Mancini Chief Operating Officer | 380,175 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 1, 2024 | Marianne Mancini Chief Operating Officer | 362,149 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.82 per share | 20,939,455.18 |
| Aug 1, 2024 | Gregory S. Zante Chief Financial Officer | 203,188 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |